Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

BLCO Bausch + Lomb Corp.

Watchlist
15.940
+0.140+0.89%
Close 07/06 16:00 ET
Giving away premium quotes worth 5000 HKD/year to unlock more data
Get NOW
High
16.250
Open
15.940
Turnover
9.77M
Low
15.895
Pre Close
15.800
Volume
609.76K
Market Cap
5.58B
P/E(TTM)
31.88
52wk High
20.200
Shares
350.00M
P/E(Static)
30.65
52wk Low
13.170
Float Cap
557.90M
Bid/Ask %
-60.00%
Historical High
20.200
Shs Float
35.00M
Volume Ratio
1.46
Historical Low
13.170
Dividend TTM
--
Div Yield TTM
--
P/B
0.78
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
1.74%
Amplitude
2.25%
Avg Price
16.014
Lot Size
1
Float Cap
557.90M
Bid/Ask %
-60.00%
Historical High
20.200
Shs Float
35.00M
Volume Ratio
1.46
Historical Low
13.170
Dividend TTM
--
P/B
0.78
Dividend LFY
--
Turnover Ratio
1.74%
Amplitude
2.25%
Avg Price
16.014
Lot Size
1
Price Forecast

No Data

News

Comment

No Data

Company Overview More
Bausch + Lomb Corporation operates as an eye health company in Canada and internationally. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that cover the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments and treatments for various eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases; and and contact lenses for therapeutic use. The Surgical segment provides medical device equipment, consumables, and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions. The company was founded in 1853 and is headquartered in Vaughan, Canada.
CEO: Papa, Joseph C.
Market: NYSE
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top